Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. - Wikidata - awgldk - TriplyDB

Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.

Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.

http://www.wikidata.org/entity/Q33637626

about

Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases Optimizing treatments for lymphangioleiomyomatosis Lymphangioleiomyomatosis: differential diagnosis and optimal management Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response.The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.Involvement of lymphatics in lymphangioleiomyomatosis Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.Lymphangioleiomyomatosis: what do we know and what are we looking for?Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis.Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.Transforming growth factor-β1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway.A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.Lymphangioleiomyomatosis: New Treatment Perspectives.Diagnosis and treatment of cystic lung disease.Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3.Emerging Roles for VEGF-D in Human Disease.Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.Emerging biomarkers of lymphangioleiomyomatosis.The LAM Lung Cell and Its Human Cell Models.Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.

P2860

Q24608283-35B6DD02-DFA0-49F5-BF5C-B90037721479 Q26865250-A819620B-3648-43A1-8A87-2EB0A2FBA016 Q27022412-B5101618-AA98-4CF7-9FBD-5BDEAF0A09D4 Q28084975-256927E8-62D9-4164-A7B2-506959562655 Q28476810-EB69D718-69C9-4A49-A970-F70BBCD49593 Q28751693-C56B7464-5E9B-4171-A5A8-7AA6AF0F996F Q30540707-C193D53D-51C0-4114-A423-F17925E21C5D Q33711691-DF6526D6-A773-4CFA-98C5-D259F853B37E Q33823877-ED674D35-FC3B-4F68-A356-FB2E60167AA2 Q33905090-50124C31-1E99-4569-AA54-9AFE027758A2 Q33905141-BF560BC3-6D26-4C44-8810-980B52EA94CC Q33905175-CD4EF2EE-A9D7-4612-9D89-27B468DB808D Q34061748-B5E9F809-D97E-41FF-B516-FD404BB1B35C Q34167429-2A30003B-4737-47D3-AC52-4677F60149CB Q34380247-1BB96B23-E902-4025-AB73-29FB102A36BE Q34536450-BEF9B0F9-1C49-437C-8402-759D25CAB905 Q34560457-BCE589C7-36AC-4D6B-BA0D-7AD682345FFC Q34598409-D8216A1E-A611-46F5-B02B-C1792193A9D3 Q35140982-937564C0-0270-46D4-AEC3-E60C492A69E5 Q35971499-5844F546-9F9F-4E05-8743-E0952F3047AD Q36015287-07C34B12-72E9-485A-A772-C10CCA1A912A Q36067383-1903A4CA-B932-4241-AEE1-2895FF7C7B8B Q36120576-46FCCF40-7D8B-464E-B014-96CB3DE2B2C2 Q36125195-4A57372A-235F-42DB-B367-1382889E03A0 Q36202928-64C26771-E355-4F6E-9E74-0BBDF4BB48BC Q36382124-617EB7AB-D2F8-46B3-95FE-AD0C4308AC7F Q37397803-90F3FCB7-5BAE-45F7-A307-B27A6B703960 Q37649952-46DF2B3A-FDBE-4093-8DAA-0F40FCCD233A Q37937344-FF9DE610-B1FB-43F2-B500-076E1C02ECAD Q38484497-9E8C0A8F-B36A-4458-A802-7B504985CBEA Q39164137-6F2A9513-7B53-41BE-98A6-5A48031802EA Q40984224-5BAA7290-8272-4B7D-BB66-94306DF2B9A2 Q47233157-583277AD-4166-4C74-9BA0-DB2790373A42 Q47370738-B5BB0A11-9AAA-4004-9EE8-FE4D26EC31D1 Q48355779-7C1F3078-847C-4B36-85B9-91391D58A70A Q49679457-66DA8E8B-44E0-4923-90D0-EBF5E8087CAD Q50181460-A3D4E19E-ACEC-4D64-8F6A-90902978ACFB Q50630588-A3F42AC9-C76D-4AFF-A68B-3FDD185C7414 Q51136450-D2BA7224-0500-443E-B296-B4D2D9EB6247 Q54495902-EB29C436-D43C-4AE9-B636-2CB6A4E49EE1

P2860

Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.

http://www.wikidata.org/entity/Q33637626

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Serum vascular endothelial gro ...... reflect lymphatic involvement.

@ast

Serum vascular endothelial gro ...... reflect lymphatic involvement.

@en

type

label

Serum vascular endothelial gro ...... reflect lymphatic involvement.

@ast

Serum vascular endothelial gro ...... reflect lymphatic involvement.

@en

prefLabel

Serum vascular endothelial gro ...... reflect lymphatic involvement.

@ast

Serum vascular endothelial gro ...... reflect lymphatic involvement.

@en

P1433

Q33637626-6CFFB57A-13B2-495B-9B55-FD331363D7F1

P1476

Q33637626-70A647E1-8DC6-4F0B-9BFD-FA2445FDBAF0

P2093

Q33637626-20282C22-5F81-4782-890B-5F024FC0681E

Q33637626-34F1C3D0-FF23-4464-961C-27D33725F981

Q33637626-5DB1281F-940A-45BD-8B10-0CF5D40F84C8

Q33637626-7F29B66B-920B-4370-9E15-53876AA97360

Q33637626-A4AF1773-A87A-45FB-AFA1-914CE92F0B06

P2860

Q33637626-21FBF418-0D1C-42A5-801D-C97E62772474

Q33637626-2290D1FF-9409-43F9-8AD6-2EFA08FE0961

Q33637626-42276927-91E5-4A8E-9FBA-E40A5DF12E29

Q33637626-45214196-AE67-4B18-BDEA-8E05E0681CBA

Q33637626-53E159B9-26CD-480B-B76B-F4C352D269DC

Q33637626-7050E46B-1A9F-4475-B991-CD0B6C25E490

Q33637626-75906335-4039-4CD8-B859-D88A822E2A89

Q33637626-848029BE-93C5-4639-80F6-78B224BA6449

Q33637626-856CDAB4-8CEE-47B0-88C2-6B9038D121D5

Q33637626-93E1346D-2CA0-4C91-8AD1-4F12DA9F94BB

P304

Q33637626-D7BFDA9E-AE3D-4C58-A7B5-821A112863F2

P31

Q33637626-D153D4D5-6DE0-4C38-A8F2-40D6EBD564F4

P356

Q33637626-FC643899-BD95-4687-A810-F8E17024797A

P407

Q33637626-88E839F4-43FF-428C-8ADE-F6416C60F28D

P433

Q33637626-2C286462-CDB8-4937-8DF4-B39BABE1F9AA

P478

Q33637626-48854880-8C2B-46CE-AE6F-480A28DD22C8

P577

Q33637626-8031CBDF-8442-4AD8-8E28-792DF6996B9A

P5875

Q33637626-16D85211-37ED-4A1B-9399-312D42100A02

P698

Q33637626-EA39E740-7AA6-44D0-B07B-A333C3D8380B

P921

Q33637626-037EAFA6-15F2-43AD-8429-E0D08FC4AF9D

P932

Q33637626-7D80BDCB-1C76-4AB9-9F95-3218F1BFCDFC

P356

P1433

P1476

Serum vascular endothelial gro ...... reflect lymphatic involvement.

@en

P2093

Connie G Glasgow

http://www.w3.org/2001/XMLSchema#string

Jing-Ping Lin

http://www.w3.org/2001/XMLSchema#string

Joel Moss

http://www.w3.org/2001/XMLSchema#string

Mario P Stylianou

http://www.w3.org/2001/XMLSchema#string

Nilo A Avila

http://www.w3.org/2001/XMLSchema#string

P2860

High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.

Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features.

Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases.

Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis.

Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.

Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.

Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism.

The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.

Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis.

P304

1293-1300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1378/CHEST.08-1160

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24406251

http://www.w3.org/2001/XMLSchema#string

P698

19420197

http://www.w3.org/2001/XMLSchema#string

P921

P932

2818417

http://www.w3.org/2001/XMLSchema#string